View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
May 6, 2021updated 12 Jul 2022 11:18am

Adagio starts Phase II/III trial for Covid-19 prevention

Adagio Therapeutics has treated the first subject in its Phase II/III EVADE clinical trial of a monoclonal antibody, ADG20, for Covid-19 prevention.

The global, multi-centre, double-blind, placebo-controlled trial will analyse a single dose of ADG20 administered intramuscularly in two independent cohorts, post-exposure and pre-exposure prophylaxis.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

The first cohort will enrol people exposed to a Covid-19 patient while the second cohort will involve people at increased risk for infection or poor response to vaccine.

EVADE will be carried out at over 100 sites across the globe and will include areas with an increased prevalence of SARS-CoV-2 virus variants.

Prevention of lab-confirmed, symptomatic Covid-19 will form the primary efficacy endpoint in the two cohorts.

Adagio commenced the EVADE trial after obtaining blinded data from ADG20’s first-in-human, randomised, placebo-controlled Phase I clinical trial in healthy subjects.

The ongoing Phase I trial is analysing the safety, tolerability, pharmacokinetics and serum SARS-CoV-2 neutralising antibody levels of different doses of the antibody treatment.

According to preliminary data, a single intramuscular ADG20 dose was well-tolerated at doses up to 600mg and its pharmacokinetic profile support an extended serum half-life, which can potentially offer protection from Covid-19 for up to a year.

Also, initial ADG20 serum virus-neutralising activity against SARS-CoV-2 is comparable to peak serum neutralising antibody titers observed in people who received a mRNA Covid-19 vaccine, Adagio said .

Adagio Therapeutics chief medical officer Lynn Connolly said: “Based on its potent and broad activity and extended duration of effect in preclinical models, we believe that ADG20 has the potential to provide both rapid protection in the face of a known, recent exposure to an individual with SARS-CoV-2 infection as well as durable protection over several months, including for individuals who are unlikely to have a sufficiently protective immune response to vaccines.”

After assessing data from the first 200 adult subjects in the Phase II part of the trial, Adagio anticipates enrolling adolescents and pregnant women in the Phase III part.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena